
---
title: '获准药物可将SARS-CoV-2感染率降低70%'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761415'
author: 科学网
comments: false
date: Fri, 06 Aug 2021 21:30:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761415'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: 黑体, SimHei;"><span style="font-size: 24px;">获准药物可将</span><span style="font-size: 24px; font-family: "arial black", "avant garde";">SARS-CoV-2</span><span style="font-size: 24px;">感染率降低</span><span style="font-size: 24px; font-family: "arial black", "avant garde";">70%</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em; text-align: center;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761415" title alt="image.png" referrerpolicy="no-referrer"> </span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><a href="https://medicalxpress.com/news/2021-08-drug-sars-cov-infection-cent-reveals.html" target="_self">Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH</a></span></p><p style="line-height: 2em;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761417" title alt="image.png" referrerpolicy="no-referrer"></p><p style="line-height: 2em;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761418" title alt="image.png" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em; text-align: center;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761419" title alt="image.png" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761420" title alt="image.png" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761421" title alt="image.png" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761422" title alt="image.png" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761423" title alt="image.png" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据英国伯明翰大学（</span><a href="http://www.bham.ac.uk/" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">University of Birmingham</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>6<span style="font-size: 18px; font-family: 宋体;">日提供的消息，该校的研究人员与英国基尔大学（</span>Keele University<span style="font-size: 18px; font-family: 宋体;">）、意大利圣拉斐尔科学研究所（</span>San Raffaele Scientific Institute Via Olgettina<span style="font-size: 18px; font-family: 宋体;">）、丹麦哥本哈根大学（</span>University of Copenhagen<span style="font-size: 18px; font-family: 宋体;">）以及英国利物浦大学（</span>University of Liverpool<span style="font-size: 18px; font-family: 宋体;">）的研究人员合作进行的一项研究显示，一种通常用于治疗血液中脂肪物质异常水平的获准药物，可将</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">病毒引起的感染减少至多</span>70%<span style="font-size: 18px; font-family: 宋体;">（</span><a href="https://medicalxpress.com/news/2021-08-drug-sars-cov-infection-cent-reveals.html" target="_self">Licensed drug could reduce SARS-CoV-2 infection by up to 70 per cent, reveals study</a><span style="font-size: 18px; font-family: 宋体;">）。相关研究结果于</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>6<span style="font-size: 18px; font-family: 宋体;">日已经在《药理学前沿》（</span>Frontiers in Pharmacology<span style="font-size: 18px; font-family: 宋体;">）杂志网站发表——</span></span><a href="https://www.frontiersin.org/people/u/488915" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Scott P. Davies</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.frontiersin.org/people/u/1268951" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Courtney J. Mycroft-West</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.frontiersin.org/people/u/1222924" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Isabel Pagani</span></a><span style="font-size: 18px; font-family: "times new roman";">, Harriet J. Hill,  Yen-Hsi Chen,  Richard Karlsson, Ieva Bagdonaite4, Scott E. Guimond, </span><a href="https://www.frontiersin.org/people/u/408400" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Zania Stamataki</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.frontiersin.org/people/u/1165344" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Marcelo Andrade De Lima</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.frontiersin.org/people/u/749101" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Jeremy E. Turnbull</span></a><span style="font-size: 18px; font-family: "times new roman";">, Zhang Yang, </span><a href="https://www.frontiersin.org/people/u/22647" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Elisa Vicenzi</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.frontiersin.org/people/u/1261784" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Mark A. Skidmore</span></a><span style="font-size: 18px; font-family: "times new roman";">, Farhat L. Khanim, </span><a href="https://www.frontiersin.org/people/u/703277" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Alan Richardson</span></a><span style="font-size: 18px; font-family: "times new roman";">. The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models. Front. Pharmacol., 06 August 2021. </span><a href="http://dx.doi.org/10.3389/fphar.2021.660490" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.3389/fphar.2021.660490</span></a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://doi.org/10.3389/fphar.2021.660490" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">https://doi.org/10.3389/fphar.2021.660490<span style="font-size: 18px; font-family: "arial black", "avant garde";">（</span></span></a><a href="http://blog.sciencenet.cn/home.php?mod=attachment&id=761416" target="_blank" class="attach" style="white-space: normal; font-size: 18px; font-family: "arial black", "avant garde";">fphar-12-660490.pdf</a><span style="font-size: 18px; font-family: "arial black", "avant garde";">）</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">由英国伯明翰大学、基尔大学和意大利圣拉斐尔科学研究所领导的研究小组在实验室中证明非诺贝特（</span><a href="https://medicalxpress.com/tags/fenofibrate/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">fenofibrate</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）及其活性形式非诺贝特酸</span>(fenofibric acid)<span style="font-size: 18px; font-family: 宋体;">可以显著减少</span>SARS-COV-2<span style="font-size: 18px; font-family: 宋体;">在人类细胞中的感染。重要的是，使用安全的药物浓度和非诺贝特标准临床剂量可达到的药物浓度来减少感染。批准使用的非诺贝特</span>,<span style="font-size: 18px; font-family: 宋体;">世界上大多数国家包括美国食品和药物管理局</span>(FDA)<span style="font-size: 18px; font-family: 宋体;">和英国国家健康和保健研究所</span>(UK's National Institute for Health and Care Excellence <span style="font-size: 18px; font-family: 宋体;">简称</span>NICE),<span style="font-size: 18px; font-family: 宋体;">是目前用于治疗血液中高胆固醇和脂肪</span>(<span style="font-size: 18px; font-family: 宋体;">脂肪物质</span>)<span style="font-size: 18px; font-family: 宋体;">的一种口服药物。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">该研究团队现在正呼吁，除了在美国宾夕法尼亚大学医院（</span>Hospital of the University of Pennsylvania<span style="font-size: 18px; font-family: 宋体;">）和以色列耶路撒冷希伯来大学（</span>Hebrew University of Jerusalem in Israel<span style="font-size: 18px; font-family: 宋体;">）正在进行的临床试验之外，也可以在其它地区的</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">住院患者当中也进行在这样的临床试验，来测试此药的有效性。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">是引起</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">的病毒，它通过病毒表面的刺突蛋白和宿主细胞上的</span>ACE2<span style="font-size: 18px; font-family: 宋体;">受体蛋白相互作用感染宿主。在这项针对全球</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">大流行的研究中，该团队测试了包括非诺贝特在内的一组已经获得许可的药物，以识别破坏</span>ACE2<span style="font-size: 18px; font-family: 宋体;">和</span>Spike<span style="font-size: 18px; font-family: 宋体;">相互作用的候选药物。在确定非诺贝特为候选药物后，他们利用</span>2020<span style="font-size: 18px; font-family: 宋体;">年分离的</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">病毒的原始毒株，在实验室中测试了该药物在减少细胞感染方面的功效。他们发现非诺贝特能减少</span>70%<span style="font-size: 18px; font-family: 宋体;">的感染。其他未发表的数据还表明，非诺贝特对新变异</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">同样有效，包括</span>α<span style="font-size: 18px; font-family: 宋体;">和</span>β<span style="font-size: 18px; font-family: 宋体;">变异，目前正在研究其对</span>δ<span style="font-size: 18px; font-family: 宋体;">变异的有效性。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">通讯作者、英国伯明翰大学的</span>Farhat Khanim<span style="font-size: 18px; font-family: 宋体;">博士解释说</span>:<span style="font-size: 18px; font-family: 宋体;">“新的传染性更强的</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">变异的发展导致世界上一些国家的感染率和死亡率迅速上升，尤其是英国、美国和欧洲。虽然疫苗项目有望在较长期内降低感染率和病毒传播，但仍迫切需要扩大我们的药物库，以治疗</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">阳性患者。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">共同通讯作者、英国基尔大学</span>(Keele University)<span style="font-size: 18px; font-family: 宋体;">的</span>Alan Richardson<span style="font-size: 18px; font-family: 宋体;">博士补充说</span>:<span style="font-size: 18px; font-family: 宋体;">“虽然在一些国家，疫苗接种计划正在快速进展，但疫苗的接种率是不稳定的，对于大多数中低收入国家来说，很大比例的人口在</span>2022<span style="font-size: 18px; font-family: 宋体;">年前不太可能接种疫苗。此外，虽然已证明接种疫苗可以降低感染率和疾病的严重程度，但我们仍不确定反应的强度和持续时间。对于出现症状或需要住院治疗的</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">患者，仍然迫切需要治疗。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">此研究报告的作者之一、意大利米兰圣拉斐尔科学研究所的</span>Elisa Vicenzi<span style="font-size: 18px; font-family: 宋体;">博士说</span>:<span style="font-size: 18px; font-family: 宋体;">“我们的数据表明，非诺贝特可能有降低</span>COVID-19<span style="font-size: 18px; font-family: 宋体;">症状的严重性和病毒传播的潜力。鉴于非诺贝特是一种口服药物、非常廉价而且可在世界范围内广泛应用</span>,<span style="font-size: 18px; font-family: 宋体;">连同其广泛的临床使用历史和良好的安全性</span>,<span style="font-size: 18px; font-family: 宋体;">我们的数据具有全球影响，特别是对中低收入国家和个人，还有那些疫苗是不推荐或不合适的人群如小孩</span>,<span style="font-size: 18px; font-family: 宋体;">患有超免疫障碍和使用免疫抑制剂的患者。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">该研究的第一作者、同样来自伯明翰大学的斯科特·戴维斯（</span><a href="https://www.frontiersin.org/people/u/488915" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Scott P. Davies</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）博士总结说</span>:<span style="font-size: 18px; font-family: 宋体;">“我们现在迫切需要进一步的临床研究，以确定非诺贝特是否是治疗</span>SARS-CoV-2<span style="font-size: 18px; font-family: 宋体;">感染的潜在药物。”上述介绍，仅供参考。欲了解更多信息敬请注意浏览</span></span><span style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><a href="https://doi.org/10.3389/fphar.2021.660490" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank">原文</a></span><span style="text-decoration: none; font-size: 18px; font-family: "arial black", "avant garde";">（</span><a href="http://blog.sciencenet.cn/home.php?mod=attachment&id=761416" target="_blank" class="attach" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";"><span style="font-size: 18px; font-family: "arial black", "avant garde";">fphar-12-660490.pdf</span></a><span style="text-decoration: none; font-size: 18px; font-family: "arial black", "avant garde";">）</span><span style="font-family: "times new roman"; font-size: 18px;">或者</span><a href="https://medicalxpress.com/news/2021-08-drug-sars-cov-infection-cent-reveals.html" target="_self" style="font-family: "times new roman"; font-size: 18px;">相关报道</a><span style="font-family: "times new roman"; font-size: 18px;">。</span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2021-08-lab-grown-heart-cells-potential-drug.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Lab-grown beating heart cells used to identify potential drug to prevent COVID-19-related heart damage</span></a></p><p style="line-height: 2em;"><a href="https://doi.org/10.3389/fphar.2021.660490" style="text-decoration: underline; font-size: 18px; font-family: "arial black", "avant garde";" target="_blank"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Abstract</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has caused a significant number of fatalities and worldwide disruption. To identify drugs to repurpose to treat SARS-CoV-2 infections, we established a screen to measure the dimerization of angiotensin-converting enzyme 2 (ACE2), the primary receptor for the virus. This screen identified fenofibric acid, the active metabolite of fenofibrate. Fenofibric acid also destabilized the receptor-binding domain (RBD) of the viral spike protein and inhibited RBD binding to ACE2 in enzyme-linked immunosorbent assay (ELISA) and whole cell-binding assays. Fenofibrate and fenofibric acid were tested by two independent laboratories measuring infection of cultured Vero cells using two different SARS-CoV-2 isolates. In both settings at drug concentrations, which are clinically achievable, fenofibrate and fenofibric acid reduced viral infection by up to 70%. Together with its extensive history of clinical use and its relatively good safety profile, this study identifies fenofibrate as a potential therapeutic agent requiring an urgent clinical evaluation to treat SARS-CoV-2 infection.</span></p><p><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1298667.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1298667.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1298627.html" target="_black">MIT新药物组合显示出早期治疗胰腺癌的潜力</a><br>                    <!--大赛结束-->
                                        
  
</div>
            